FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Laurence Choné et al.|New England Journal of Medicine|2018Cited by 2.8k
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThierry Conroy, Antoine Adenis, Marie‐Pierre Galais et al.|The Lancet Oncology|2014Cited by 446
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322